Key result
CRT-P cuts all-cause mortality ~32% and reduces heart failure hospitalizations or death.
Why the study?
The study aimed to identify patient characteristics that predict the specific effect of CRT pacemakers (CRT-P) on all-cause mortality or HF hospitalization without confounding from concomitant defibrillator therapy.
Does CRT-P reduce all-cause mortality and the composite of heart failure hospitalization or mortality in patients with heart failure, reduced LVEF, QRS >130 ms, and sinus rhythm?
Meta-Analysis (n=1,738)
Yes
Does CRT-P reduce all-cause mortality and the composite of heart failure hospitalization or mortality in patients with heart failure, reduced LVEF, QRS >130 ms, and sinus rhythm?
Effect estimate: HR 0.68 (95% CI 0.56-0.81)
p-value: p=<0.0001
CRT-P significantly reduces all-cause mortality and the composite of heart failure hospitalization or mortality in appropriately selected heart failure patients, with potentially greater benefits in smaller patients and those receiving beta-blockers.
No takes yet. Share an insight, caveat, or question.
Supports CRT-P implantation in eligible HF patients with reduced LVEF and wide QRS; strengthens randomized evidence for mortality benefit.
Cleland et al. (2022) conducted a meta-analysis in Heart failure (n=1,738). Cardiac resynchronization therapy pacemakers (CRT-P) vs. Control was evaluated on All-cause mortality (HR 0.68, 95% CI 0.56-0.81, p=<0.0001). Cardiac resynchronization therapy pacemakers significantly reduced all-cause mortality (HR 0.68; 95% CI 0.56-0.81; p<0.0001) and the composite of heart failure hospitalization or mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: